Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study

<div>DAAs regimens for HCV genotype 1b and 2a in the real-world study. The number and proportion of different DAAs regimens for HCV genotype 1b (a) and 2a (b) are presented by different colors in the graphs. DAAs: direct-acting antivirals; OBV/PTV/r: ombitasvir/paritaprevir/ritonavir; DSV: dasabuvir; SOF: sofosbuvir; RBV: ribavirin; EBR/GZR: elbasvir/grazoprevir; VEL: velpatasvir; DCV: daclatasvir; ASV: asunaprevir; LDV: ledipasvir; GLE/PIB: glecaprevir/pibrentasvir; and DNV: danoprevir.</div>

Canadian Journal of Gastroenterology and Hepatology

fig3

Figure 3

Figure 3: Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study 

Figure 3 | Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study 